MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Myriad Genetics Inc (MYGN) is not a strong buy for a beginner investor with a long-term strategy. The technical indicators show mixed signals, the financial performance is weak, and there are no significant positive catalysts or trading signals to justify an immediate investment. Holding off for now would be prudent.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting an overall downtrend. The stock is trading near its pivot point of 4.548, with resistance at 4.807 and support at 4.288.
The MACD histogram is positive, showing some bullish momentum. The stock has a 60% chance of gaining 1.78% in the next week.
Weak financial performance in Q4 2025 with significant YoY declines in revenue (-0.38%), net income (-81.41%), and EPS (-82.98%). Analysts have lowered price targets, and there is no recent news or significant insider/hedge fund activity to suggest a turnaround.
In Q4 2025, revenue dropped to $209.8M (-0.38% YoY), net income fell to -$7.9M (-81.41% YoY), EPS dropped to -$0.08 (-82.98% YoY), and gross margin declined to 69.97% (-2.34% YoY).
Analysts have lowered price targets recently (UBS to $6 from $8, Wells Fargo to $6 from $6.50, TD Cowen to $7 from $9) and maintain neutral or hold ratings, citing the need for more progress on turnaround strategies and pipeline execution.
